Robert Ticktin sold $25k of PMVP
General Counsel & COO at PMV Pharmaceuticals, Inc.. 23,151 shares at an average of $1.06, traded Jul 1, 2025, filed Jul 3, 2025.
Score components
- +20RoleCOO
- 0Trade size$25k at market
- +5Share of holdings soldSold 19% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-019386, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 1, 2025 | SOpen-market sale Common Stock | -23,151 | $1.06 | $25k | 98,695 | Jul 3, 2025 |
Related signals
Other insiders at PMV Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | PMVPsell PMV Pharmaceuticals, Inc. | Orbimed Advisors LLC owner | $1.5M 1,000,000 shares | -17% | |
| 36Weak | PMVPsell PMV Pharmaceuticals, Inc. | Orbimed Advisors LLC owner | $900k 500,000 shares | -8% | |
| 52Moderate | PMV Pharmaceuticals, Inc. | Michael Carulli Chief Financial Officer | $30k 28,249 shares | -32% | |
| 46Moderate | PMV Pharmaceuticals, Inc. | Deepika Jalota Chief Development Officer | $35k 33,065 shares | -27% | |
| 47Moderate | PMV Pharmaceuticals, Inc. | David Henry Mack President and CEO | $62k 58,411 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.